GURUFOCUS.COM » STOCK LIST » USA » NYSE » Merck & Co Inc (NYSE:MRK) » Definitions » Revenue
Switch to:

Merck (NYSE:MRK) Revenue

: $58,311 Mil (TTM As of Jun. 2023)
View and export this data going back to 1949. Start your Free Trial

Merck's revenue for the three months ended in Jun. 2023 was $15,035 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $58,311 Mil. Merck's Revenue per Share for the three months ended in Jun. 2023 was $5.92. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $22.91.

Warning Sign:

Merck & Co Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Merck was 1.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 9.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Merck's highest 3-Year average Revenue per Share Growth Rate was 22.80% per year. The lowest was -16.50% per year. And the median was 8.40% per year.


Merck Revenue Historical Data

The historical data trend for Merck's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42,294.00 39,121.00 41,518.00 48,704.00 59,283.00

Merck Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,593.00 14,959.00 13,830.00 14,487.00 15,035.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Merck Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's Revenue distribution charts can be found below:

* The bar in red indicates where Merck's Revenue falls in comparison to its industry or sector. The grey bar indicates the Revenue's extreme value range as defined by GuruFocus.



Merck Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $58,311 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck  (NYSE:MRK) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Merck Revenue Related Terms

Thank you for viewing the detailed overview of Merck's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (NYSE:MRK) Business Description

Merck logo
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Cristal N Downing officer: Chief Comm. & Public Afrs Ofcr 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Michael A Klobuchar officer: EVP - Chief Strategy Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lisa Lecointe-cephas officer: SVP Chief Ethics & Com Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Dean Y Li officer: Executive VP & President, MRL 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Christine E Seidman director MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathy J Warden director 2980 FAIRVIEW PARK DRIVE, FALLS CHURCH VA 22042

Merck (NYSE:MRK) Headlines

From GuruFocus